Shares of Amgen, Inc. (NASDAQ:AMGN) have been assigned a consensus rating of “Hold” from the twenty-one ratings firms that are currently covering the firm, MarketBeat Ratings reports. Eleven investment analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $210.24.

Several equities analysts have commented on AMGN shares. Morgan Stanley dropped their target price on Amgen from $213.00 to $212.00 and set an “overweight” rating for the company in a research report on Wednesday, December 19th. Citigroup increased their target price on Amgen from $204.00 to $210.00 and gave the company a “neutral” rating in a research report on Friday, January 4th. Zacks Investment Research raised Amgen from a “hold” rating to a “buy” rating and set a $225.00 price target for the company in a research note on Monday, January 14th. Royal Bank of Canada reissued a “neutral” rating and issued a price target on shares of Amgen in a research note on Monday, January 14th. Finally, Goldman Sachs Group reissued a “buy” rating and issued a $232.00 price target on shares of Amgen in a research note on Thursday, January 17th.

In related news, Director Ronald D. Sugar sold 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 3rd. The stock was sold at an average price of $193.18, for a total transaction of $386,360.00. Following the completion of the sale, the director now owns 15,092 shares of the company’s stock, valued at $2,915,472.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 6,000 shares of company stock valued at $1,144,120 in the last ninety days. 0.27% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AMGN. Ruggie Capital Group grew its stake in Amgen by 297.1% during the fourth quarter. Ruggie Capital Group now owns 135 shares of the medical research company’s stock worth $26,000 after purchasing an additional 101 shares during the period. Arlington Partners LLC grew its stake in Amgen by 86.7% during the fourth quarter. Arlington Partners LLC now owns 140 shares of the medical research company’s stock worth $27,000 after purchasing an additional 65 shares during the period. Capital Financial Planning LLC acquired a new stake in Amgen during the fourth quarter worth approximately $27,000. Massey Quick Simon & CO. LLC grew its stake in Amgen by 710.5% during the fourth quarter. Massey Quick Simon & CO. LLC now owns 154 shares of the medical research company’s stock worth $30,000 after purchasing an additional 135 shares during the period. Finally, Next Capital Management LLC acquired a new stake in Amgen during the fourth quarter worth approximately $33,000. 79.18% of the stock is owned by institutional investors and hedge funds.

Amgen stock traded down $0.22 during trading hours on Monday, hitting $191.20. The stock had a trading volume of 1,961,266 shares, compared to its average volume of 2,938,669. The company has a current ratio of 2.79, a quick ratio of 2.57 and a debt-to-equity ratio of 2.36. The company has a market capitalization of $117.91 billion, a PE ratio of 13.28, a P/E/G ratio of 2.35 and a beta of 1.21. Amgen has a one year low of $165.22 and a one year high of $210.19.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, January 29th. The medical research company reported $3.42 EPS for the quarter, beating the consensus estimate of $3.26 by $0.16. The firm had revenue of $6.23 billion during the quarter, compared to the consensus estimate of $5.88 billion. Amgen had a return on equity of 66.74% and a net margin of 35.35%. During the same period last year, the company earned $2.89 earnings per share. As a group, analysts predict that Amgen will post 13.97 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be paid a dividend of $1.45 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $5.80 annualized dividend and a yield of 3.03%. Amgen’s dividend payout ratio is currently 40.28%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

See Also: Why are trading ranges significant?

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.